High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer

High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer

The comparison of the genetic profiles between primary and metastatic colorectal cancer (CRC) is needed to enable the discovery of useful therapeutic targets against metastatic CRCs. We performed the targeted next generation sequencing assay of 170 cancer-associated genes for 142 metastatic CRCs, in...

Full description

Bibliographic Details
Main Authors:	Seung Eun Lee, Ha Young Park, Dae-Yong Hwang, Hye Seung Han
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	International Journal of Molecular Sciences
Subjects:	metastatic colorectal cancer genomic profiles high concordance between primary and metastatic colorectal cancer
Online Access:	https://www.mdpi.com/1422-0067/22/11/5561

Similar Items

Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing
by: M. B. Mogensen, et al.
Published: (2018-07-01)

CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: V. A. Ekimov
Published: (2015-02-01)

CLINICAL EXPERIENCE OF PROLONGED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: A. F. Saidullaeva
Published: (2015-02-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan N. Davidov
Published: (2013-12-01)

Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions
by: Alessandro Ottaiano, et al.
Published: (2022-01-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Yi-Chia Su, et al.
Published: (2022-04-01)

The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases
by: Stacey A. Cohen, et al.
Published: (2017-05-01)

Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer
by: Sarah C. Markt, et al.
Published: (2023-01-01)

The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
by: I V Poddubnaya, et al.
Published: (2014-03-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
by: Letizia Procaccio, et al.
Published: (2021-10-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

SHORT-TERM RESULTS OF SIMULTANEOUS SURGERIES AT METASTATIC COLORECTAL CANCER
by: A. S. Zagaynov, et al.
Published: (2017-02-01)

The Effect Of Chemotherapy On Malnutrition In Geriatric Group With Metastatic Colorectal Cancer
by: Esat Namal
Published: (2019-01-01)

Expert consensus on maintenance treatment for metastatic colorectal cancer in China
by: Rui-Hua Xu, et al.
Published: (2016-01-01)

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
by: Celso Abdon Lopes de Mello, et al.
Published: (2022-12-01)

Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy
by: Zhiming Wang, et al.
Published: (2016-09-01)

Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer
by: Yi-Hsuan Huang, et al.
Published: (2021-12-01)

Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis
by: Bradley Ashley Gue Ong, et al.
Published: (2022-04-01)

Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country
by: Lana Jajac-Bručić, et al.
Published: (2021-01-01)

Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?
by: Yakup Ergun, et al.
Published: (2020-01-01)

THE HIGH ACTIVITY OF VECTIBIX IN PATIENTS WITH METASTATIC COLORECTAL CANCER WITH THE RAS WILD-TYPE GENE
by: N. N. Semenov
Published: (2015-02-01)

Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
by: Gerhard Jung, et al.
Published: (2020-10-01)

An Unconventional Regimen of Carboplatin and Paclitaxel in Metastatic Colorectal Carcinosarcoma: A Case Report and Review of Literature
by: Changsu Lawrence Park, et al.
Published: (2023-05-01)

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
by: Sadayuki Kawai, et al.
Published: (2021-02-01)

Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study
by: Deiana Roman, et al.
Published: (2022-06-01)

Analysis of the role of RAS Family Mutations in Metastatic Colorectal Cancer (mCRC): Current Treatment Practice
by: Saridaki Zenia, et al.
Published: (2014-12-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
by: Dalyong Kim, et al.
Published: (2017-11-01)

Cetuximab in first line treatment of metastatic colorectal cancer
by: Carlo Barone, et al.
Published: (2012-07-01)

An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients
by: Li Liang, et al.
Published: (2018-10-01)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
by: Kristian Blomberg, et al.
Published: (2021-10-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
by: Jorge Aparicio, et al.
Published: (2020-11-01)

Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians
by: Eric Van Cutsem, et al.
Published: (2016-08-01)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
by: Diana Cornelia Moisuc, et al.
Published: (2023-02-01)

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)